I-Sorafenib CAS 284461-73-0 Purity ≥99.0% (HPLC) API Factory High Quality
I-Commercial Supply Sorafenib Tosylate kanye Nezixhumanisi Ezihlobene:
I-Sorafenib Tosylate CAS: 475207-59-1
I-Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
| Igama | I-Sorafenib |
| Omqondofana | I-Sorafenib Free Base |
| Inombolo ye-CAS | 284461-73-0 |
| Inombolo yeCAT | I-RF-API04 |
| Isimo Sesitoko | Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu |
| I-Molecular Formula | I-C21H16ClF3N4O3 |
| Isisindo samangqamuzana | 464.82 |
| Ukuminyana | 1.454±0.06 g/cm3 |
| Ukuncibilika | I-Soluble ku-DMSO |
| Imibandela Yokuthumela | I-Ambient Temperature |
| Ibhrendi | I-Ruifu Chemical |
| Into | Imininingwane |
| Ukubukeka | Impushana Emhlophe Kuya Kumhlophe |
| Ukuhlanzeka / Indlela Yokuhlaziya | ≥99.0% (HPLC) |
| Ukuhlonza | H-NMR, MS |
| Ukulahlekelwa Ekumisweni | ≤1.0% |
| Izinsalela ekushiseni | ≤0.10% |
| Ukungcola Okukodwa | ≤0.20% (HPLC) |
| Ukungcola Okuphelele | ≤1.0% (HPLC) |
| Izinsimbi Ezisindayo | ≤20ppm |
| Ukucaca Kwesixazululo | Vumelana Nezinga |
| Izinga Lokuhlola | I-Enterprise Standard |
| Ukusetshenziswa | I-RCC ne-HCC |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, isigubhu seCardboard, 25kg/Drum, noma ngokwezidingo zekhasimende.
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni, umswakama kanye nezinambuzane.
I-Sorafenib Tosylate (CAS: 475207-59-1) iwuhlobo olusha lwesidakamizwa esilwa nesimila esihloselwe izinto eziningi, sathuthukiswa yi-German Bayer Pharmaceuticals, futhi yabonisa umsebenzi wokulwa nesimila owandayo ekuhlolweni kwezilwane ngaphambi komtholampilo.I-Sorafenib itholakala kumaphilisi angu-200-mg ukuze iphathwe ngomlomo futhi isetshenziselwa ukwelapha i-RCC ne-HCC.I-Sorafenib Tosylate (CAS: 475207-59-1) ingathinta kanyekanye amaseli e-tumor kanye nemithambo yegazi yesimila.Inomphumela we-antitumor ophindwe kabili: ingavimba izindlela zokudluliselwa kwesignali yeseli exhunywe yi-RAF/MEK/ERK ukuze ivimbele ngokuqondile ukukhula kwe-tumor cell, kuyilapho ivimbela i-VEGF kanye ne-platelet derived growth factor (PDGF) receptors ukuvimbela ukwakheka kwegazi elisha lesimila. imikhumbi, ngaleyo ndlela ivimbele ngokungaqondile ukukhula kwamangqamuzana e-tumor.I-Sorafenib iyi-inhibitor ye-Raf-1 ne-B-RAF kanye nama-tyrosine kinases amaningana.
